Martek Biosciences Shares Fall Upon Reaffirmation of Second
Quarter Revenue Forecast
Martek Biosciences Corp. (MATK) shares fell, falling to $34.80 after the
company reaffirmed its second-quarter revenue forecast of $55 million.
Martek revised its third-quarter revenue forecast to a range of $38 million
to $42 million; revised its fourth-quarter revenue outlook to a range of $61
million to $76 million; and revised lower its fiscal 2005 revenue outlook to
a range of $220 million to $240 million.
